American pharmaceutical company Eli Lilly announced last week that it had seen encouraging clinical trial results of its new Alzheimer’s medication.
According to the company, their experimental drug, donanemab, was shown in a late-stage trial to slow cognitive decline by 35 percent.
While these results do sound promising, the full data is not yet released, so there’s still a lot we don’t know.
Comments are closed.